Thursday, October 29, 2026
Goldman Sachs kept its Neutral rating on Viking Therapeutics (VKTX) and lowered its price target to $34 from $38.
Tuesday, October 20, 2026
H.C. Wainwright kept its Buy rating on Viking Therapeutics (VKTX) with a price target of $106.
Frequently asked questions
What is the latest news on VKTX?
Oct 29, 2026: Goldman Sachs kept its Neutral rating on Viking Therapeutics (VKTX) and lowered its price target to $34 from $38. (Goldman Sachs) · Oct 20, 2026: H.C. Wainwright kept its Buy rating on Viking Therapeutics (VKTX) with a price target of $106. (H.C. Wainwright)
What are analysts saying about VKTX?
Oct 29, 2026: Goldman Sachs kept its Neutral rating on Viking Therapeutics (VKTX) and lowered its price target to $34 from $38. · Oct 20, 2026: H.C. Wainwright kept its Buy rating on Viking Therapeutics (VKTX) with a price target of $106.
Get VKTX news as it happens
Every headline, SEC filing and analyst action for VKTX on your live chart, with important news marked and alerts when it matters.
Try SEPT Free